טוען...
Approved LXR agonists exert unspecific effects on pancreatic β-cell function
Novel agonists of the nuclear liver-X-receptor (LXR) are designed to treat metabolic disorders or cancer. The rationale to develop these new drugs is based on promising results with established LXR agonist like T0901317 and GW3965. LXRα and LXRβ are expressed in β-cells, and expression is increased...
שמור ב:
| הוצא לאור ב: | Endocrine |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7308254/ https://ncbi.nlm.nih.gov/pubmed/32146655 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12020-020-02241-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|